Quarterly ResultMay 13, 2026, 04:08 PM
Bionano Q1 Revenue +4% to $6.7M; Gross Margin 49%
AI Summary
Bionano Genomics reported its first quarter 2026 financial results, with total revenue increasing 4% to $6.7 million and consumables revenue growing 20% to $3.9 million. The company also saw a 17% increase in nanochannel array flow cell sales and an improvement in gross margin to 49%. Operating expenses decreased by 2% to $11.1 million. Key business highlights include the effectiveness of a new Category I CPT code for OGM and a 47% increase in payment for another OGM-related CPT code, alongside expanding evidence and adoption of its optical genome mapping technology. The company provided Q2 2026 revenue guidance of $7.5-$7.8 million and full-year guidance of $30-$33 million.
Key Highlights
- Bionano Q1 2026 total revenue increased 4% to $6.7 million.
- Consumables revenue grew 20% to $3.9 million.
- Sold 8,178 nanochannel array flow cells, up 17% YoY.
- Gross margin improved to 49% from 46% in Q1 2025.
- GAAP operating expenses reduced by 2% to $11.1 million.
- New Category I CPT code (81354) for OGM became effective January 1, 2026.
- CPT code 81195 payment determination increased 47% to $1,853.22.
- Q2 2026 revenue guidance set at $7.5 million to $7.8 million.
- Full year 2026 revenue guidance is $30 million to $33 million.